Dec 24 2009
Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”). Under the shelf registration statement, when declared effective by the SEC, Unigene may offer and sell, from time to time in the future in one or more public offerings, up to $30 million of equity or debt securities or any combination thereof. The Company does not have any immediate plans or current commitments to sell securities. The specific terms of any future offering, including the prices, and use of proceeds will be determined at the time of any such offering and will be described in detail in a prospectus supplement which will be filed with the SEC at the time of the offering.
“The shelf registration gives Unigene the flexibility to access additional capital at some point in the future when market conditions are appropriate”
“The shelf registration gives Unigene the flexibility to access additional capital at some point in the future when market conditions are appropriate,” commented Dr. Warren Levy, President and CEO of Unigene Laboratories, Inc.
Unigene’s shelf registration statement has been filed with the SEC but has not yet become effective. The securities registered may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state of jurisdiction. Any offering of the securities covered by the registration statement will only be by means of a prospectus and an accompanying prospectus supplement.
Source:
Unigene Laboratories, Inc.